Ty-Jour T1 - 经修订的耐药结核病患者的影响JF - 欧洲呼吸杂志Jo - Eur Respir J Do - 10.1183 / 13993003 - 2100641-2021 SP - 2100641 Au - Veziris，尼古拉斯，尼古拉斯·奥 - 邦特，伊莎贝尔Au - 莫雷尔，佛罗伦萨Au - Guglielmetti，Lorenzo Au - Maitre，Thomas Au - Fournier Le Ray，Laure Au - Sougakoff，Wladimir Au - Robert，JérômeAu - Au - Aubry，Alexandra A2 - ，Y1 - 2021/01/01 US - http：// Erj。ersjournals.com/content/early/2021/04/29/13993003.00641-2021.Abstract N2 - 最近，世界卫生组织（世卫组织）发布了应该使用的广泛耐药结核病（XDR-TB）的修订定义对于从2021年1月1日开始的临床和监视目的[1,2]。除了多药耐药之外，XDR-Tb Tb的先前定义是耐氟喹啉（左氧氟沙星和/或嘌呤氧化乙酰辛）和三种二线可注射药物（SLI，辣椒霉素，卡那霉素）中的至少一种耐氟喹啉（SLI，Capreomycin，Kanamycin）。。修订后的定义是：结核分枝杆菌菌株引起的结核病，其满足MDR / RR-TB的定义，并且对任何氟喹啉和至少一种药物也抵抗含量。谁对药物目前包括氟喹诺酮（左氧氟沙星或莫西沙星），LINEzolid和BEDAQUILIN。此外，预先XDR-TB现在是具有任何氟喹诺酮抗性的MDR / RR-TB的世卫组织认可的定义。虽然先前的XDR-TB的定义已经证明了差的治疗结果差的预测[3]，但2020更新符合近期治疗方案的变化，较少使用SLI以有利于有效的口腔药物Bedaquiline和Linezolid。此外，大的Meta分析未能显示死亡率降低和SLI使用之间的关联，而该关联显示为Bedaquiline和Linezolid [4]。 In this study, we aimed to measure retrospectively the impact of the revised definition on the epidemiology of XDR-TB in France.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: That the national reference centre receives an annual grant from SantéPublique France; that the laboratory in which they work has received a research grant from Janssen for a study on bedaquiline. ER -